Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. has successfully completed the conversion of 54,268,364 unlisted shares into H shares, marking the completion of its H share full circulation. This strategic move enhances the company’s market presence by increasing the liquidity of its shares, as the converted H shares will be listed on the Stock Exchange starting July 22, 2025. The company’s share capital structure now consists entirely of H shares, which could potentially attract more investors and improve stakeholder confidence.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative therapeutics, particularly in the field of oncology, and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 26,377,316
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.33B
For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.